Acurx Pharmaceuticals, Inc.
ACXP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACXP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACXP
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel antibiotic for recurrent C. difficile infection, with a Phase 2b trial underway and a cash position of $10.7M as of 2026-06-30.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for Acurx Pharmaceuticals, Inc..
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel antibiotic for recurrent C. difficile infection, with a Phase 2b trial underway and a cash position of $10.7M as of 2026-06-30.
- Acurx is developing a product candidate for recurrent Clostridioides difficile infection (rCDI) and plans to seek FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) [sec · filed 2026-03-09].
- The company is enrolling up to 20 patients with at least two recurrences in the past 12 months in a Phase 2b trial, with first-patient enrollment expected in Q4 2026 [sec · filed 2026-03-09].
- Cash and equivalents were $10.7M as of 2026-06-30, with a net loss of $2.3M for the quarter ended June 30, 2026 [sec].
- Shareholders' equity was $0.6M as of 2026-06-30, indicating a thin equity base [sec].
- The company outsources clinical trial activities to CROs and other third-party service providers, and plans to substantially increase R&D expenses for the foreseeable future [sec_mda · as of 2026-05-11].
What works
- Acurx has a defined regulatory pathway (LPAD) for its rCDI candidate, which may allow for a more streamlined approval process if pivotal data are positive [sec · filed 2026-03-09].
- The Phase 2b trial design is intended to inform a planned active-controlled Phase 3 registration trial, showing a clear development roadmap [sec · filed 2026-03-09].
- The company raised net proceeds of approximately $2.5 million in June 2025 via a warrant inducement, demonstrating some access to capital [sec_mda · as of 2026-03-12].
What to weigh
- Cash of $10.7M as of 2026-06-30 is limited for a clinical-stage company, and the company acknowledges it could deplete capital sooner than expected [sec_mda · as of 2026-03-12].
- Shareholders' equity of $0.6M as of 2026-06-30 is very low, reflecting accumulated losses and a thin capital base [sec].
- The company has no revenue expected for the foreseeable future and faces uncertainties in clinical trial costs, timelines, and regulatory outcomes [sec_mda · as of 2026-03-12].
- The Phase 2b trial is small (up to 20 patients) and may not be sufficient to support registration without a larger Phase 3 study [sec · filed 2026-03-09].
From the filings
Quoted directly from source documents.
Phase 2b trial enrollment criteria and timeline
“will enroll up to 20 patients who have experienced at least two recurrences within the past 12 months. Trial start-up activities are scheduled to begin later this month, and first-patient enrollment is expected in the fourth quarter of this year.”
SEC filings · March 9, 2026
Regulatory pathway under LPAD
“Following a successful pivotal Phase 3 study, the Company plans to seek the United States Food and Drug Administration's approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for treatment and prevention of rCDI.”
SEC filings · March 9, 2026
Risk of capital depletion
“we could deplete our capital resources sooner than we expect.”
SEC MD&A · March 12, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $10.7M as of 2026-06-30 may not be sufficient to complete planned trials without additional financing [sec].
- Clinical trial execution risk — Phase 2b trial is small (20 patients) and delays or negative results could derail the development plan [sec · filed 2026-03-09].
- Regulatory uncertainty — LPAD pathway is limited; FDA may require additional data or a larger Phase 3 trial before approval [sec · filed 2026-03-09].
- No revenue and accumulated losses — Company has no revenue expected for the foreseeable future and has a thin equity base of $0.6M [sec].
What to watch
- First-patient enrollment in the Phase 2b rCDI trial, expected in Q4 2026 [sec · filed 2026-03-09].
- Any updates on cash position or additional financing activities, given the limited runway [sec].
- Regulatory feedback from the FDA on the Phase 2b data and the design of the planned Phase 3 trial [sec · filed 2026-03-09].
- Progress in manufacturing and CRO relationships, as the company outsources substantial clinical activities [sec_mda · as of 2026-05-11].
Sources: SEC filings · SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run Acurx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acurx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
18.7 months
D/E 0.35 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$640K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 62,198 | $231K |
| jane street group, llc | 54,642 | $203K |
| geode capital management, llc | 24,819 | $92K |
| vanguard fiduciary trust co | 16,205 | $60K |
| morgan stanley | 6,500 | $24K |
| wells fargo & company/mn | 2,300 | $9K |
| nbc securities, inc. | 1,500 | $6K |
| western wealth management, llc | 1,325 | $5K |
| tower research capital llc (trc) | 1,031 | $4K |
| mcguire capital advisors inc | 1,000 | $4K |
Showing top 10 of 19 institutional holders of Acurx Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.2%
- Days to cover
- 0.6
- Shares short
- 114,951
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACXP short interestFrequently asked questions
What is the AI investment thesis for Acurx Pharmaceuticals, Inc.?
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel antibiotic for recurrent C. difficile infection, with a Phase 2b trial underway and a cash position of $10.7M as of 2026-06-30.
What is Acurx Pharmaceuticals, Inc.'s lead drug candidate?
Acurx Pharmaceuticals, Inc.'s most advanced tracked candidate is ACX-375C (Preclinical) for Gram-positive bacteria, including MRSA, VRE and PRSP.
Who is the CEO of Acurx Pharmaceuticals, Inc.?
Mr. David P. Luci CPA, Esq., J.D. is the chief executive officer of Acurx Pharmaceuticals, Inc. (ACXP).
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc. (ACXP) is headquartered in Staten Island, NY, United States.
What therapeutic areas does Acurx Pharmaceuticals, Inc. focus on?
Acurx Pharmaceuticals, Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.